OR WAIT null SECS
Chiltern International Limited (Chiltern) announced an additional financial investment in Endpoint Clinical, Inc. (endpoint) further strengthening their strategic partnership with the company established in April 2009.
Glenn Kerkhof, Chiltern CEO, stated, “Chiltern’s decision to increase our investment in endpoint reflects our aligned vision for the future of endpoint’s PULSE platform, enabling endpoint to provide a combination of premium client service and advanced technology solutions. Jon Dole and Tom O’Connell of endpoint have brought a new level of energy and innovation to Interactive Response Technology (IRT).”
PULSE is endpoint’s fully configurable system which allows users to design and deploy clinical trial IRT systems at a fraction of the time and cost of other providers, was launched in January 2010.PULSE simultaneously designs systems that can be accessed via the phone, web, or mobile device.